Prolonged impacts of COVID-19-associated cystitis: A study on long-term consequences

Table 1 Demographics of study population at 10-14 wk and at 21-28 mo, n (%)

	Initial urologic assessment (10-14 wk)	Follow up urologic assessment (21-28 mo)
Patients (n)	350	310
Age [median(range)]	64.5 (47-82)	64 (47-82)
Gender
Female	140 (40)	130 (42)
Male	210 (60)	180 (58)
Ethnicity
Black	305 (87)	280 (90)
White	45 (13)	30 (10)
Onset of symptoms
New	250 (71)	220 (71)
Worsening	100 (29)	90 (29)
BPH	110 (52)	80 (44)

BPH: Benign prosthetic hypertrophy.

Table 2 Outcomes assessment

	Initial urologic assessment (10-14 wk)		Follow up urologic assessment (21-28 mo)
	OAB symptom score median (range)	QoL score median (range)	OAB symptom score median (range)	Qol score median (range)
New symptoms (n = 250)a	18 (12-21)	19 (16-24)	9 (4-21)	9 (7-20)
Worsening symptoms (n = 100)b	19 (17-21)c	20 (19-20)c	13 (5-21)	14 (6-20)
Female (n = 140)	18 (15-21)	19 (16-21)	8 (4-21)	7 (6-22)
Male (n = 210)	18 (12-20)	19 (16-20)	7 (5-20)	8 (6-23)

^a30 patients lost to follow up.

^b10 patients lost to follow up.

^cPre-COVID OAB and QoL median score: 8 (range 4-10) and 9 (8-10) respectively.

CAC: COVID-associated cystitis; OAB: Overactive bladder; QoL: Quality of life.